84766-90-5

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl(4-oxobutyl)carbamic acid is used as a synthetic intermediate for the production of Nα-(N,N-Dimethylcarbamoyl)-α-azaornithine and α-azalysine esters. These esters act as trypsin, chymotrypsin, and thrombin inhibitors, playing a crucial role in the development of therapeutic agents for various medical conditions.
Used in Chemical Research:
tert-butyl(4-oxobutyl)carbamic acid is also used as an intermediate in the synthesis of Spermidine-d6 Trihydrochloride (S680407), a labeled Trihydrochloride derivative of Spermidine (S680400). Spermidine is a biogenic polyamine essential for both normal and neoplastic tissue growth, and its labeled derivative can be utilized in research to study the biological processes involving polyamines.

Upstream product

• 75178-87-9 (4-hydroxybutyl)carbamic acid tert-butyl ester 
• 201230-82-2 carbon monoxide 
• 78888-18-3 N-tert-butoxycarbonylprop-2-en-1-amine 
• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 143646-48-4 4-(tert-butoxycarbonylamino)butyraldehyde diethyl acetal 

Downstream Products

• 1181216-39-6 C₃₆H₄₄N₂O₅ 
• 872554-77-3 Fmoc-aza-β3-Orn(Boc)-Bn 
• 85909-04-2 4-tert-butoxycarbonylaminobutyric acid methyl ester 
• 142181-96-2 1(4-tert-butyloxycarbonylaminobutyl)-hydrazine dicarboxylic acid-2-dimethylamide-1-p-nitrophenylester 
• 142181-95-1 1(4-tert-butyloxycarbonylaminobutyl)-hydrazine dicarboxylic acid-2-dimethylamide-1-phenylester 
• 781642-15-7 [(6E,10E)-(4R,8S,12S)-8-(tert-Butyl-diphenyl-silanyloxy)-12-hydroxy-4-methoxymethoxy-pentadeca-6,10,14-trienyl]-carbamic acid tert-butyl ester 
• 781642-14-6 [(6E,10E)-(4R,8S)-8-(tert-Butyl-diphenyl-silanyloxy)-4-methoxymethoxy-12-oxo-dodeca-6,10-dienyl]-carbamic acid tert-butyl ester 
• 781642-13-5 [8-(tert-butyl-diphenyl-silanyloxy)-4-methoxymethoxy-undeca-6,10-dienyl]-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

De-novo designed β-lysine derivatives can both augment and diminish the proliferation rates of E. coli through the action of Elongation Factor P

An investigation into the effect of modified β-lysines on the growth rates of eubacterial cells is reported. It is shown that the effects observed are due to the post translational modification of Elongation Factor P (EFP) with these compounds catalysed b

Divergent Electrochemical Carboamidation of Cyclic Amines

We developed an electrochemical carboamidation sequence that affords either cyclic β-amidoamine products via direct functionalization or linear hydroxybisamide products via a ring opening pathway. The reaction pathway was dependent on the nature of the N-acyl activating group, with carbamate groups favoring direct isocyanide addition to the N-acyliminium ion intermediate and the benzoyl activating group favoring the ring opening–functionalization pathway. Both protocols are one-pot reaction sequences, have general applicability, and lead to peptide-like products of greatly increased molecular complexity.

BICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

Stable peptide-based PACE4 inhibitors

It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the PACE4 inhibitors or the composition disclosed.

MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION

The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.

α-Amino Acid-Isosteric α-Amino Tetrazoles

The synthesis of all 20 common natural proteinogenic and 4 otherα-amino acid-isosteric α-amino tetrazoles has been accomplished, whereby the carboxyl group is replaced by the isosteric 5-tetrazolyl group. The short process involves the use of the key Ugi tetrazole reaction followed by deprotection chemistries. The tetrazole group is bioisosteric to the carboxylic acid and is widely used in medicinal chemistry and drug design. Surprisingly, several of the common α-amino acid-isosteric α-amino tetrazoles are unknown up to now. Therefore a rapid synthetic access to this compound class and non-natural derivatives is of high interest to advance the field.

QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.

Easily accessible and highly tunable bisphosphine ligands for asymmetric hydroformylation of terminal and internal alkenes

An efficient methodology for synthesizing a small library of easily tunable and sterically bulky ligands for asymmetric hydroformylation (AHF) has been reported. Five groups of alkene substrates have been tested with excellent conversions, moderate-to-excellent regio- and enantioselectivities. Among the best result of the reported literature, application of ligand 1 c in the highly selective AHF of the challenging substrate 2,5-dihydrofuran yielded almost one isomer in up to 99 % conversion along with enantiomeric excesses (ee) of up to 92 %. Highly enantioselective AHF of dihydropyrrole substrates is achieved using the same ligand, with up to 95 % ee and up to >1:50 β-isomer/α- isomer ratio. The simpler the better! An efficient method for the easy and tunable synthesis of a series of asymmetric hydroformylation (AHF) ligands from low-cost, commercially available starting materials has been reported. These ligands can give excellent conversions and moderate to excellent regio- and enantioselectivities for a broad range of mono- and disubstituted alkenes with a low catalyst loading (substrate-to-catalyst ratios (S/C) of 1000:1 to 3000:1).

A convergent total synthesis of (+)-febrifugine

Febrifugine was synthesized in ten steps from N-Boc 4-aminobutan-1-ol by a convergent approach. Georg Thieme Verlag Stuttgart.

Synthesis and inhibiting properties toward trypsin like proteases of N(α)-(N,N-dimehtylcarbamoyl)-α-azaornitine and α-azalysine esters

N(α)-(N,N-dimethylcarbamoyl)-α-azaornithine and N(α)-(N,N-dimethylcarbamoyl)-α-azalysine phenyl and p-nitrophenyl esters (7-10) were synthesized and tested as inhibitors of trypsin, chymotrypsin and thrombin. The N,N-dimethylcarbamoyl group was chosen to decrease the tendency of acylcarbazates to cyclization into 1,3,4-oxadiazol-2(3H)-ones. Only the p-nitrophenyl α-azaornithine derivative 8 was inactivated rapidly by intramolecular acylation of the terminal amino group, rather than by cyclization to oxadiazolone, in aqueous solution at pH 8. The corresponding α-azalysine derivative 10 is completely unaffected under the same conditions. Rapid inactivation of thrombin and trypsin only was observed for all α-azapeptide esters 7-10 at 0.5 mM inhibitor concentration. No proteolytic activity was restored after 24 h following 2000 fold dilution of the inhibitor concentration suggesting formation of very stable acylenzymes.